Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)
Clinical trial NCT04676997 · UNKNOWN
Trial details
- NCT number
- NCT04676997
- Sponsor
- Shandong Cancer Hospital and Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-20
- Primary completion
- 2021-07-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.